Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$7.35
+0.4%
$7.01
$4.07
$18.86
$464.81M1.631.27 million shs1.27 million shs
Journey Medical Co. stock logo
DERM
Journey Medical
$3.40
-2.9%
$3.73
$1.02
$8.11
$67.76M0.8185,762 shs64,845 shs
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$9.25
$9.22
$3.46
$9.28
$420.52M1.3840,890 shs178,496 shs
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$329.83
$325.43
$158.38
$329.99
$12.58B1.18832,048 shs5 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
+7.17%+12.27%+7.81%+8.12%-59.33%
Journey Medical Co. stock logo
DERM
Journey Medical
+2.94%-2.23%-5.15%+349,999,900.00%+349,999,900.00%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.00%0.00%0.00%0.00%0.00%
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00%0.00%0.00%+5.04%+71.40%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
3.1066 of 5 stars
3.41.00.04.50.91.70.0
Journey Medical Co. stock logo
DERM
Journey Medical
2.176 of 5 stars
3.53.00.00.00.92.50.6
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.1136 of 5 stars
1.20.00.00.00.91.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
2.75
Moderate Buy$14.2593.88% Upside
Journey Medical Co. stock logo
DERM
Journey Medical
3.00
Buy$8.50150.00% Upside
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
2.38
Hold$293.92-10.89% Downside

Current Analyst Ratings

Latest KIN, KRTX, DERM, and CDMO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/14/2024
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$330.00
3/7/2024
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$7.00
2/20/2024
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$330.00
2/16/2024
Journey Medical Co. stock logo
DERM
Journey Medical
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.50
1/26/2024
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$245.00 ➝ $330.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$149.27M3.11$0.17 per share44.28$3.03 per share2.43
Journey Medical Co. stock logo
DERM
Journey Medical
$79.18M0.86$0.18 per share18.77$1.05 per share3.24
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$42.16M9.97N/AN/A$1.75 per share5.29
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$654K19,239.07N/AN/A$33.24 per share9.92

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$560K-$0.27N/AN/A-13.10%-8.68%-3.63%6/19/2024 (Estimated)
Journey Medical Co. stock logo
DERM
Journey Medical
-$3.85M-$0.35N/AN/AN/A-4.87%-34.08%-5.00%5/27/2024 (Estimated)
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%5/2/2024 (Estimated)

Latest KIN, KRTX, DERM, and CDMO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/21/2024Q4 2023
Journey Medical Co. stock logo
DERM
Journey Medical
N/A-$0.12-$0.12-$0.12$15.80 million$15.26 million
2/22/2024Q4 2023
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
-$2.65-$3.01-$0.36-$3.01$0.86 millionN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
N/AN/AN/AN/AN/A
Journey Medical Co. stock logo
DERM
Journey Medical
N/AN/AN/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
0.81
1.35
0.85
Journey Medical Co. stock logo
DERM
Journey Medical
0.72
1.35
1.10
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.19
7.02
7.02
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/A
19.31
19.31

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
97.16%
Journey Medical Co. stock logo
DERM
Journey Medical
7.25%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
66.89%
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
2.39%
Journey Medical Co. stock logo
DERM
Journey Medical
19.42%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
13.69%
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
13.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
36563.24 million61.73 millionOptionable
Journey Medical Co. stock logo
DERM
Journey Medical
4119.93 million16.06 millionN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
6345.46 millionN/AOptionable
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
33938.15 million33.16 millionOptionable

KIN, KRTX, DERM, and CDMO Headlines

SourceHeadline
Bristol Myers posts quarterly loss, lays out $1.5 billion cost-saving planBristol Myers posts quarterly loss, lays out $1.5 billion cost-saving plan
investing.com - April 25 at 7:35 PM
After Karunas acquisition, former CEO lands new gig at Cambridge biotechAfter Karuna's acquisition, former CEO lands new gig at Cambridge biotech
bizjournals.com - April 22 at 4:24 PM
Nvelop and Seaport Raise $100M in Rounds, Tap Bluebird and Karuna ExecsNvelop and Seaport Raise $100M in Rounds, Tap Bluebird and Karuna Execs
biospace.com - April 11 at 3:42 AM
Seaport Therapeutics has $100 million to develop new ways to treat mental disordersSeaport Therapeutics has $100 million to develop new ways to treat mental disorders
msn.com - April 9 at 5:53 PM
Big biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swellsBig biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swells
statnews.com - April 9 at 7:50 AM
China Universal Asset Management Co. Ltd. Purchases 3,392 Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX)China Universal Asset Management Co. Ltd. Purchases 3,392 Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX)
marketbeat.com - April 4 at 6:54 PM
Karuna Therapeutics, Inc. (NASDAQ:KRTX) Given Average Rating of "Hold" by AnalystsKaruna Therapeutics, Inc. (NASDAQ:KRTX) Given Average Rating of "Hold" by Analysts
marketbeat.com - April 4 at 2:31 AM
Bristol Myers Squibb concludes acquisition of Karuna TherapeuticsBristol Myers Squibb concludes acquisition of Karuna Therapeutics
medicaldialogues.in - March 21 at 4:52 AM
Bristol Myers Squibb Completes Acquisition of Karuna TherapeuticsBristol Myers Squibb Completes Acquisition of Karuna Therapeutics
njbmagazine.com - March 18 at 10:40 PM
Loss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-TermLoss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-Term
finance.yahoo.com - March 15 at 10:15 AM
KRTX May 2024 210.000 callKRTX May 2024 210.000 call
ca.finance.yahoo.com - March 15 at 5:15 AM
Analysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Cannabist Company Holdings (OtherCBSTF)Analysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Cannabist Company Holdings (OtherCBSTF)
markets.businessinsider.com - March 14 at 7:13 PM
Pricing watchdog offers lukewarm reception to KarXTPricing watchdog offers lukewarm reception to KarXT
thepharmaletter.com - March 12 at 4:05 PM
Karuna Therapeutics, Inc. (NASDAQ:KRTX) Insider Sells $1,591,700.00 in StockKaruna Therapeutics, Inc. (NASDAQ:KRTX) Insider Sells $1,591,700.00 in Stock
insidertrades.com - March 12 at 4:39 AM
Bronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short PositionBronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short Position
finance.yahoo.com - March 4 at 12:19 PM
Karuna Therapeutics drops on no apparent news amid deal with Bristol-Myers SquibbKaruna Therapeutics drops on no apparent news amid deal with Bristol-Myers Squibb
msn.com - February 26 at 1:04 PM
Karunas (KRTX) Q4 Loss Widens, Focus on Bristol Myers BuyoutKaruna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
zacks.com - February 23 at 12:11 PM
1KRTX : Karuna Therapeutics: Q4 Earnings Insights1KRTX : Karuna Therapeutics: Q4 Earnings Insights
benzinga.com - February 23 at 7:53 AM
Karuna Therapeutics GAAP EPS of -$3.01 misses by $0.29Karuna Therapeutics GAAP EPS of -$3.01 misses by $0.29
msn.com - February 22 at 11:45 AM
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
finance.yahoo.com - February 22 at 6:45 AM
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
businesswire.com - February 22 at 6:30 AM
Bronte Capital - Karuna Therapeutics: A Rare Mistake With A Natural Test Of ProcessBronte Capital - Karuna Therapeutics: A Rare Mistake With A Natural Test Of Process
seekingalpha.com - February 21 at 7:15 AM
Karuna Therapeutics: Getting Sold ShortKaruna Therapeutics: Getting Sold Short
seekingalpha.com - February 18 at 1:38 PM
KRTX Mar 2024 320.000 callKRTX Mar 2024 320.000 call
finance.yahoo.com - February 17 at 3:43 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Avid Bioservices logo

Avid Bioservices

NASDAQ:CDMO
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Journey Medical logo

Journey Medical

NASDAQ:DERM
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
Kindred Biosciences logo

Kindred Biosciences

NASDAQ:KIN
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.
Karuna Therapeutics logo

Karuna Therapeutics

NASDAQ:KRTX
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.